Relief for Acute Nose and Throat Symptoms

This medication is generally used in situations involving symptoms related to physical discomfort associated with acute upper respiratory tract infections, such as the common cold (rhinopharyngitis) and discomfort in the throat or sinuses. The application is relevant for easing symptoms related to localized irritative states. It is applied to address symptom clusters that may appear suddenly, including nasal congestion, irritation, and localized swelling, and may provide support that helps ease the overall symptom burden.

---

Supportive Management of Localized Infection-Related Symptoms

Locabiosol is considered relevant in clinical settings marked by increased discomfort or tension caused by localized irritative states within the upper airways. It is commonly used across conditions presenting with acute episodes like rhinitis, sinusitis, tonsillitis, or pharyngitis. The therapy is applied in contexts where additional symptomatic support is needed, supports patients during episodes of heightened discomfort, and may assist with managing symptoms that interfere with daily comfort. The medication supports patients during episodes of heightened discomfort.

---

Quick Fact: Use Category: Symptomatic Support

The official eligibility status for the use of Locabiosol (fusafungine) is defined by its mandatory market withdrawal in several major global regions, including all European Union Member States, as mandated by their regulatory bodies.

Eligibility Scope

Category	Regulatory Status
Populations Allowed Use	None, in jurisdictions where marketing authorization has been officially revoked (e.g., EU).
Populations Contraindicated	Individuals with known hypersensitivity to fusafungine or any excipients. The general population in regions where authorization is revoked.
Age-Related Rules	Contraindicated in children under 30 months due to the risk of laryngeal spasm, a specific regulatory exclusion. Not authorized for any age group following revocation.
Physiological Restrictions	Prior labeling advised caution in pregnant women and those with a history of allergic conditions or bronchospasm. No dose adjustment was typically required for patients with renal or hepatic impairment.

Official Eligibility Structure

The primary regulatory constraint is the revocation of marketing authorization for fusafungine-containing medicines, a measure taken following a review by the European Medicines Agency (EMA). This decision was based on a negative benefit-risk assessment due to the potential for serious allergic reactions, including life-threatening bronchospasm. This official action formally removed the drug's eligibility for use by the general public in affected countries.

Interactions with Other Medicines and Products

The regulatory interaction profile for Locabiosol (Fusafungine) is defined by the product’s localized application and the official status of interaction testing. Fusafungine is administered topically to the oromucosal and nasal linings, resulting in minimal and transient systemic exposure.

Interaction Category	Official Regulatory Statement
Formal Interaction Study Status	No interactions studies have been performed to formally document drug–drug, drug–food, or drug–supplement interactions.
Contraindicated Combinations	None are explicitly documented in the regulatory label based on formal interaction data or identified risk.
Metabolic/Transporter Interactions	None are documented. No specific metabolic (CYP) or transporter-mediated interaction profiles are detailed in the official prescribing information.
Timing or Administration Rules	None are stated. No mandatory separation times are required for the co-administration of this medicine with other products.

---

The absence of documented systemic interactions is consistent with the compound’s negligible concentration in the bloodstream following topical use. Consequently, the official labeling does not include restrictions, specific mechanistic warnings, or prohibitions regarding co-administration with other medicines or substances. The preparation does contain a small amount of ethanol (alcohol) as an inactive ingredient, but this excipient is not listed as a formal interaction risk with external alcohol consumption or other medications.

The mechanism of action for Fusafungine is defined by its dual local activity, modulating the underlying biological processes of both inflammation and microbial growth directly at the oromucosal and nasal surfaces.

---

Modulating the Local Inflammatory Cascade

This domain focuses on the molecule's chemical interaction with immune cells. Fusafungine acts by inhibiting the synthesis and release of pro-inflammatory mediators, such as Interleukin-1 beta (IL-1beta) and TNF-alpha, from activated macrophages. This mechanistic step directly dampens the chemical signals that cause vascular permeability and fluid accumulation, resulting in reduced fluid accumulation and decreased tissue volume at the site of administration.

---

Interfering with Pathogen Growth and Adhesion

This mechanism involves a bacteriostatic and fungistatic interaction with susceptible microorganisms found on the respiratory lining. By restricting the cellular processes necessary for microbial replication and growth, and by inhibiting the adhesion of pathogens to the epithelial cells, the drug limits the population density of the infectious agent. This sequence limits the biological input that drives the sustained local inflammatory reaction.

---

Synergy of Dual Mechanistic Action

The combination of the anti-inflammatory action with the microbial growth inhibition creates a functional synergy that targets both the cause and the response of the local pathology. This concurrent, localized action disrupts the pathological cycle through the combined effect of reduced mediator synthesis and suppressed microbial replication.

Administration Scope

The pressurized aerosol spray containing 125 micrograms of Fusafungine per puff is administered via the oromucosal (mouth) and nasal (nose) routes.

Property	Detail
Route of administration	Topical delivery via Oromucosal and Nasal inhalation
Dosing schedule (Adults)	4 puffs in the mouth and 2 puffs in each nostril
Dosing schedule (Children > 30 months)	2 puffs in the mouth and (or) 1 puff in each nostril
Course Duration	Treatment should normally last 7 days. Use must be discontinued if improvement is not observed after this period.
Frequency pattern	4 times daily for both adult and specified pediatric populations
Population Restrictions	Not for use in children aged 0 to 30 months. No dose adjustment is specified as necessary for older adults or patients with renal or hepatic impairment.

Preparation and Procedural Structure

The correct use of the medicine requires specific procedural steps. Before the initial administration, the valve must be primed by pressing the main actuator four times.

Step sequence:

• Prime the valve by pressing the main actuator 4 times before the very first use.
• The bottle must be held upright during the administration process.
• The appropriate adaptor (mouth or nose) must be correctly positioned.
• The spray should be delivered by pressing firmly and at length on the adaptor while maintaining normal breathing.
• If a dose is forgotten, the patient should continue with the prescribed schedule and must not take a double dose to compensate.

Connection to the overall use protocol: The protocol establishes a standardized, fixed-dose regimen applied locally to the upper respiratory tract. This protocol dictates the exact number of puffs, the frequency (four times daily), and the specific administration technique to correctly deliver the specified dose. The protocol further limits the course of therapy to a maximum of 7 days, unless improvement occurs sooner, establishing clear parameters for the duration of use.

Locabiosol is a trade name for the substance fusafungine, an antibiotic and anti-inflammatory agent previously used as a nasal and oral spray for upper airway infections, such as pharyngitis, laryngitis, and rhinitis.

---

Regulatory Status and Risk Review

Unlike many medications with updated trial data, the most significant recent evidence concerning fusafungine relates to a comprehensive safety and efficacy review conducted by the European Medicines Agency (EMA) in the 2010s.

• Benefit-Risk Assessment: The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) concluded that the benefits of fusafungine did not outweigh its risks for all authorized uses. This assessment was based on the generally mild and self-limiting nature of upper airway infections.
• Efficacy Evidence: Reviews determined the clinical evidence supporting the beneficial effects of fusafungine was weak. A Cochrane review, for instance, concluded that the outcomes were not relevant in clinical practice.
• Safety Concerns: The review noted the occurrence of serious allergic reactions, including life-threatening bronchospasm (severe breathing difficulties), following the use of fusafungine sprays. Although rare, the risk could not be sufficiently managed.

---

Market Withdrawal

Following the EMA review and consensus from the Co-ordination Group for Mutual Recognition and Decentralised Procedures (CMDh), the marketing authorizations for fusafungine-containing medicines, including Locabiosol, were revoked across the European Union (EU) in 2016.

This decision was due to the combination of the lack of strong efficacy evidence and the potential for rare but serious allergic reactions. Fusafungine is not approved for use in the United States by the U.S. Food and Drug Administration (FDA).

Official Storage and Handling Requirements

Storage and disposal requirements for Locabiosol (fusafungine) are strictly defined by regulatory documents, particularly concerning its status as a pressurized aerosol.

Requirement Type	Official Labeled Instruction
Temperature Restriction	Must be stored at a temperature not exceeding 25 C or 30 C (limit varies by region).
Prohibited Environment	Do not refrigerate and do not freeze the product.
Protection	Keep in the original packaging and protect from heat and direct sunlight.
Child Safety	Mandatory to keep out of the sight and reach of children.
Disposal	Dispose of unused or expired product according to local regulations for pharmaceutical waste.
Container Handling	The pressurized canister must not be punctured or burned, even when empty; do not dispose of in wastewater or household trash.